Can you imagine if you were lucky enough to own thousands of shares in a biotech that has achieved the following?

Following are the conclusions of the analysis of apabetalone done by the pharmacology students at Qatar University. It was sponsored by the university.

Key Excerpts from Qatar Apebetalone Review Feb 15 2024

Apabetalone Reduces Endothelial Dysfunction and Vascular Inflammation

Conclusion

ARTICLE SECTIONS

Jump To

Apabetalone shows promising potential as a therapeutic agent for various diseases, particularly cardiovascular and chronic kidney diseases.  

By targeting the BD2 of BRDs, apabetalone inhibits the activity of BET proteins at the transcriptional level and thwarts the downstream effects on genes involved in maladaptive responses in inflammation, oxidative stress, and renal and cardiovascular diseases. (31,35,38,58) 

Notably, apabetalone

• increases apoA-I and HDL levels,
• lessens inflammation,
• reduces ALP and vascular calcification,
• downregulates the complement pathway, and decreases oxidative stress. (29−31,33,35,36,38,44,58) 

As such, apabetalone is the first of its class to instigate such a wide range of therapeutic effects in non-oncological indications. Indeed, preclinical and clinical studies have also demonstrated multiple convincing beneficial effects of apabetalone in cardiovascular, renal, neurological, and viral diseases. (29−31,33,36,44,60,66,74) 

Adding to this, a handful of preliminary studies have investigated the potential of apabetalone in several types of cancer such as rhabdomyosarcoma, ovarian cancer, and colorectal cancer. (83−85) 

With its ability to impact multiple diseases, apabetalone presents itself as a novel therapeutic strategy beyond its primary application in cardiovascular diseases.

Considering the broad implications of epigenetic modifications, particularly lysine acetylation, it is conceivable that apabetalone may prove beneficial in treating numerous other disorders using preclinical animal models.

Ongoing investigations aim to uncover further therapeutic effects of apabetalone and possible combination therapies that may further enhance the protective role of apabetalone.

Given that the drug is novel and is still in clinical trials, further preclinical research and clinical trials are warranted to fully explore the therapeutic potential of apabetalone in a wide range of oncological and non-oncological disease contexts.

Author Information

ARTICLE SECTIONS

Jump To

• Corresponding Author
• Zaid H. Maayah - Department of Pharmaceutical Sciences, College of Pharmacy, QU Health, Qatar University, Doha 2713, Qatar;  https://orcid.org/0000-0003-0276-9916; Email: almaayah@qu.edu.qa
• Authors
• Hevna Dhulkifle - Department of Pharmaceutical Sciences, College of Pharmacy, QU Health, Qatar University, Doha 2713, Qatar
• Mohammad Issam Diab - Department of Pharmaceutical Sciences, College of Pharmacy, QU Health, Qatar University, Doha 2713, Qatar
• Majed Algonaiah - Department of Pharmacology & Toxicology, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia
• Hesham M. Korashy - Department of Pharmaceutical Sciences, College of Pharmacy, QU Health, Qatar University, Doha 2713, Qatar;  https://orcid.org/0000-0002-5745-9643
•  
• Funding

This publication was supported by Qatar University Internal Grant No. QUCG-CPH-23/24-209. The findings achieved herein are solely the responsibility of the authors.

• Notes

The authors declare no competing financial interest.

References

ARTICLE SECTIONS

Jump To

This article references 87 other publications.

So with these remarkable results how on earth is RVX in the terrible situation that it is in at this stage.

You would have to have the most incompetent management team on earth to not have your shares in high demand at very high prices with such medical potential.

And you would have to be remarkably incompetent as a financing team to NOT be attracting lots of money to finance the many indications that apabetalone could be a benefit to.

RVX, please recognize you need help.

• sell
• or hire a biotech CEO
• but at least do something of value for once.

GLTA

Toinv